Barclays keeps Danaher at Overweight and lifts Elevance price target to $472
According to Dow Jones Newswires, Barclays kept Overweight ratings on Danaher and Elevance Health and raised its Elevance target to $472 from $469 a share.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Barclays kept its Overweight rating on Danaher (DHR). For Elevance Health (ELV), the bank also kept Overweight and increased its price target to $472 per share from $469.
Dow Jones Newswires reported the rating actions, citing Benzinga data. The notice does not say what drove the analysts' decisions.
why it matters
Changes like these reflect analysts' views on each company and rarely move the broader market. A $3 increase in a price target is a small adjustment, so investors may focus more on company results and the overall sector trend.
tags
instruments
sources
- Elevance Health Is Maintained at Overweight by Barclays — Dow Jones Newswires, 22 October 2026 at 15:59 UTC
- Danaher Is Maintained at Overweight by Barclays — Dow Jones Newswires, 22 October 2026 at 15:58 UTC
- IBM Is Maintained at Overweight by Barclays — Dow Jones Newswires, 22 October 2026 at 16:07 UTC
- Pegasystems Is Maintained at Overweight by Barclays — Dow Jones Newswires, 22 October 2026 at 16:38 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗